Veloxis's Envarsus XR gets FDA approval to treat kidney transplant patients

Denmark-based Veloxis Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Envarsus XR (tacrolimus extended-release tablets) to treat kidney transplant patients.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news